Background Endoscopic ampullectomy is increasingly performed in patients with familial adenomatous polyposis (FAP)-associated ampullary adenomas. We sought to define the procedure-associated morbidities and long-term outcomes. Methods We performed a retrospective chart review of patients with FAP who underwent endoscopic ampullectomy at two tertiary institutions between 1999 and 2010. The severity of duodenal polyposis was classified according to Spigelman's classification. Results Of 26 FAP patients who underwent endoscopic ampullectomy, 21 arose in the setting of Spigelman's stage II duodenal polyposis. Adverse events associated with endoscopic ampullectomy included acute pancreatitis (19.2 %), abdominal pain (7.6 %), and bleeding (3.8 %). The mean resected adenoma size was 0.99 ± 0.34 cm. Three adenomas (12.0 %) contained foci of high-grade dysplasia. Follow-up data were available for 24 patients. The mean follow-up duration was 84.5 ± 36.2 months. Adenoma recurrence was observed in 14 patients (58.3 %; 14/24) at a mean of 38.3 months after initial ampullectomy. Adenomas C10 mm recurred more frequently than smaller adenomas (76.9 vs. 36.4 %; p = 0.002). Positive margins were not associated with higher recurrence rates. No cancers were observed during long-term follow-up. Three patients underwent a Whipple procedure, but none was performed for a recurrent ampullary adenoma. Conclusions Endoscopic ampullectomy in FAP can be performed safely. Because ampullary adenomas frequently recur after endoscopic ampullectomy, close surveillance is essential. Smaller tumors are less likely to recur, suggesting a benefit for early recognition of these lesions.
Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited disorder caused by germline mutations in the APC gene. In the classic form of FAP, colonic polyposis develops in over 90 % of affected individuals by age 35 years. The lifetime risk of colorectal cancer is nearly 100 % in the absence of colectomy [1] . The duodenum is the second most common site of polyp formation. Observed in up to 90 % of individuals with FAP, duodenal polyps are usually recognized 10-20 years after the diagnosis of colonic polyposis. Duodenal/periampullary adenocarcinoma is the second most common cause of cancer death in FAP, and the cumulative risk of duodenal cancer is estimated to be as high as 10 % by age 60 years, which is 100-to 300-fold higher than the general population [1, 2] .
Ampullary tumors develop via an adenoma-to-carcinoma sequence, as observed in the colon [3] . These lesions are increasingly identified in asymptomatic patients by surveillance endoscopy. Management options include local or extended surgical resection [including pancreaticoduodenectomy (PD), pancreas-sparing duodenectomy (PSD), or transduodenal excision (TDE)] and endoscopic resection [4] [5] [6] . Although outcomes from surgery may be excellent, morbidity and mortality rates are not insignificant (range 4-15 %) and depend upon the experience of the hospital and the surgeon [7] . Furthermore, FAP patients may be poor operative candidates due to abdominal desmoid disease.
Although surgery is indicated in cases of duodenal and ampullary cancer, less invasive endoscopic approaches are now commonly performed in FAP patients with benign ampullary adenomas. However, there are limited data on long-term outcome associated with this procedure. It is unknown what long-term recurrence rates are and whether removal of ampullary adenomas prevent adenocarcinoma. The goal of this study was to define procedure-associated morbidities and long-term recurrence rates after endoscopic ampullectomy for ampullary adenomas in FAP patients.
Patients and methods
We performed a retrospective chart review and identified patients who underwent endoscopic ampullectomy for a histologically defined ampullary adenoma and also carried a diagnosis of FAP at the Massachusetts General Hospital and Brigham and Women's Hospital between the years 2000 and 2010. Patients who had a diagnosis of ampullary adenocarcinoma were excluded, and those who developed ampullary adenomas in the absence of a diagnosis of FAP were excluded. The diagnosis of FAP was established by the presence of a germline APC mutation and/or clinical criteria, including diffuse colonic adenomatous polyposis, extracolonic manifestations including fundic gland polyposis, duodenal or ampullary adenomas, osteomas, desmoid tumors, and a family history of FAP. APC gene testing was performed commercially in Clinical Laboratory Improvement Act (CLIA)-approved laboratories.
Data extracted from medical records included age, gender, extracolonic manifestations, results of upper and lower gastrointestinal endoscopic examinations, colectomy, endoscopic ampullectomy, and genetic testing. The severity of duodenal polyposis was assessed by the Spigelman classification [8] , and the severity of acute pancreatitis was assessed by Ranson's severity index. All slides from resected ampullary adenomas were reviewed by one pathologist for the presence of dysplasia and the involvement of lateral and deep resection margins. This study was approved by the Institutional Review Boards of Massachusetts General Hospital and Brigham and Women's Hospital.
Statistical analysis
Statistical analysis included the Chi square test, Fisher's exact test, Cox proportional hazard regression analysis, Kaplan-Meier method, and log-rank test. Data were presented as mean ± SD. The Chi square test was used to determine whether there was an association between positive margins and the resection method (en bloc vs. piecemeal resection), or association between positive margins and ampullectomy technique (submucosal injection of saline). Cox regression analysis was used to evaluate the impact and correlation of multiple variables to recurrence. The recurrence-free function was estimated by the Kaplan-Meier method, and the significance was analyzed by the log-rank test. A p value of \0.05 was considered statistically significant.
Results

Patient characteristics
The study group consisted of 26 patients with FAP who underwent endoscopic ampullectomy between the years 2000 and 2010. Seventeen patients were female (65 %) and nine were male (35 %). Fifteen patients had deleterious germline mutations in the APC gene. Genetic testing was not performed in the remaining 11 patients, and their diagnoses were established by clinical criteria, including a personal history of colonic polyposis, FAP-associated extracolonic manifestations, and a positive family history of FAP. Mean age at diagnosis of FAP was 27.8 ± 9.9 years (range 16-47 years). Among men, the mean age was 36.1 ± 7.1 years (range 27-47 years) and mean age of the women was 23.4 ± 8.2 years (range 16-46 years) ( Table 1 ; p = 0.001).
Ampullary adenomas were diagnosed at a mean age of 40.4 ± 13.8 years (range 19-76 years). Mean age among men was 42.0 ± 14.6 years (range 26-76 years), and 39.5 ± 13.8 years among women (range 19-63 years) (p = 0.43). In seven patients (26.9 %), diagnosis was made by biopsy of an endoscopically normal-appearing ampulla.
Fifteen of the 26 cases (57.7 %) were diagnosed at the first upper endoscopic examination performed for screening. The remaining 11 cases were diagnosed at subsequent surveillance examinations. Three patients who were diagnosed at their second surveillance endoscopy did not have a targeted biopsy of a normal-appearing ampulla at their first endoscopy. The distributions of Spigelman stages of duodenal polyposis at the time of initial diagnosis were: stage I (1 case; 3.8 %), stage II (21 cases; 80.9 %), stage III (3 cases; 11.5 %), and stage IV (1 case; 3.8 %). This patient with Spigelman stage IV disease had significant concurrent illnesses, including morbid obesity, prior abdominal surgery, chronic obstructive lung disease, and insulin-dependent diabetes. For these reasons, a non-surgical approach was initially pursued.
Colectomies had previously been performed in 23 cases, and colorectal cancer was diagnosed in three cases. The mean age of colectomy was 30.7 ± 8.1 years (range 17-47 years). Three patients did not undergo colectomy. In one patient, the number of colonic polyps was relatively stable and low (*20). The second patient refused surgery. The third patient had attenuated FAP, and the relatively small number of colonic adenomas (*3-4 polyps at each annual colonoscopic examination) was managed endoscopically. Six patients (23.1 %) were diagnosed with an extracolonic malignancy prior to ampullectomy; these are described in Table 2 .
Ampullectomy technique
All ampullectomies were performed on an outpatient basis. Submucosal lifting with saline injection was performed in five patients. Two methods were used for ampullectomyen bloc resection in 17 patients (65.4 %) and piecemeal resection in the remaining nine patients (34.6 %). Postampullectomy stent placement was attempted in all patients and was successful in 19 patients (73.1 %). In nine patients, both a pancreatic and a biliary stent were placed. A single pancreatic stent was placed in nine patients, and a single biliary stent was placed in one patient. Stents were not successfully placed in the remaining seven cases (26.9 %).
Pathology of ampullectomy specimens
Twenty-five of the 26 resected ampullary polyps were evaluated pathologically (Table 3 ). In one case, the sample was not successfully retrieved. All the ampullary tumors were benign adenomas, and the mean adenoma size was 0.99 ± 0.34 cm (range 0.4-2.0 cm). In three patients (12.0 %), high-grade dysplasia (HGD) was identified within the adenoma, and the mean size of these three adenomas was 1.10 ± 0.20 cm (range 0.9-1.3 cm). The mean size of adenomas resected en bloc was 0.90 ± 0.28 cm (range 0.4-1.2 cm) and 1.16 ± 0.40 cm (range 0.7-2.0 cm) for those resected piecemeal.
Positive resection margins were identified in 16 cases (64.0 %). Of these, 13 patients (52.0 %) had lateral resection margin involvement by adenomatous tissue, and 11 patients (44.0 %) showed deep margin involvement. In eight patients (32.0 %), both resection margins were involved by adenomatous tissue. There was no difference in the rate of positive resection margins with respect to the method of resection (en bloc resection vs. piecemeal resection; p = 0.495) or submucosal injection of saline (p = 0.22).
Follow-up after ampullectomy and adverse events
Two patients did not return for follow-up upper endoscopic examinations after the initial ampullectomy. The remaining 24 patients who presented for follow-up were analyzed. Mean duration of follow-up was 84.5 ± 36.2 months (range 19-153 months). Overall, 208 follow-up procedures were performed among these 24 patients, including 180 esophagogastroduodenoscopies (EGDs), 21 endoscopic retrograde cholangiopancreatographies (ERCPs) and 7 enteroscopies (Table 4 ). The mean interval between follow-up procedures was 12.2 ± 5.6 months (range 1-56 months). The mean number of follow-up endoscopies was 8.6 ± 6.0 per patient (range 2-26 examinations). Eight of the 26 patients (30.8 %) experienced an acute adverse event after the initial ampullectomy. The most frequent adverse event was acute pancreatitis that required admission (n = 5; 19.2 %). Three patients had one Ranson's severity criteria of acute pancreatitis, while the remaining two patients met no severity criteria. Pancreatitis resolved in all cases with conservative treatment. The median length of hospital stay was 2.8 ± 1.3 days (range 2-5 days). Acute pancreatitis occurred in two patients who received a pancreatic stent, and also in three patients who did not.
One patient had severe abdominal pain attributed to spontaneous biliary stent migration into the small bowel. This resolved with conservative management. Another patient developed epigastric pain and was hospitalized for 2 days. The third patient had hematemesis and hematochezia and was admitted for 3 days with transfusion of two units of red blood cells. Bleeding was controlled with epinephrine injection to the ampullectomy site.
Seven patients experienced adverse events related to procedures performed during the follow-up surveillance interval (29.2 %; 7/24). The most frequent adverse events in this post-ampullectomy surveillance interval were acute pancreatitis (16.7 %; 4/24) and ampullary stenosis (16.7 %; 4/24) ( Table 4) . One case of pancreatitis was severe and was complicated by acute respiratory distress syndrome. This procedure involved biopsy of two small nodules at the ampullectomy site, and the pathologic analysis revealed adenoma. No stent insertion was performed. The patient required hospitalization for 14 days (including an ICU stay for 10 days). The second patient developed post-ERCP pancreatitis without placement of a pancreatic stent and had a second episode at an ERCP 9 years later that did include pancreatic stent placement. The third patient developed pancreatitis 2 days after ERCP, and the fourth patient developed pancreatitis after an ampullary biopsy. These latter three patients recovered within 2-3 days of admission with conservative management. Post-ampullectomy stenosis occurred in four patients at a mean interval from the initial ampullectomy of 75.0 ± 39.3 months (range 19-111 months). Sphincterotomy with placement of biliary and pancreatic stents was performed in three patients, and balloon papilloplasty was performed for mild stenosis in the fourth patient.
Adenoma recurrence
Among the 24 patients who had follow-up endoscopic examinations, adenoma recurrence was detected in 14 patients (58.3 %) over a mean follow-up period of 84.5 ± 36.2 months. The mean interval to recurrence was 38.3 ± 37.9 months (range 7-110 months). Biopsy-proven recurrence was detected in two patients with endoscopically normal ampullae (14.3 %; 2/14). Specific details regarding these 14 recurrences are described in Table 5 . Among these 14 patients, six patients were diagnosed at their first follow-up upper gastroduodenal endoscopy. Patients who had an adenoma \10 mm had a mean recurrence-free interval of 95.8 ± 9.7 months (range 16-110 months; median 104 months), and the overall recurrence rate in this group was 36.4 % (4/11). However, those with an adenoma C10 mm had a significantly shorter recurrence-free interval of 34.7 ± 8.9 months (range 7-56 months; median 16 months), and the overall recurrence rate increased to 76.9 % (10/13; p = 0.002) (Fig. 1) . Cox multivariate regression analysis indicated that larger adenoma size was an independent predictor of recurrence (p = 0.04), and there was no significant correlation between age, Spigelman stage, resection method, positive margin, history of duodenal adenoma and/or fundic gland polyps and recurrence of ampullary adenoma (p = 0.93, 0.07, 0.19, 0.71, 0.64, respectively). No invasive ampullary cancers were diagnosed during follow-up.
Patients who had their adenomas removed en bloc had a 46.7 % recurrence rate (7/15), and patients who had a piecemeal resection exhibited a 77.8 % recurrence rate (7/9) (p = 0.29). The mean recurrence-free intervals were 74.3 ± 10.7 months (range 13-104 months; median 91 months) and 46.6 ± 16.3 months (range 7-110 months; median 16 months), respectively. Although there was a trend towards a greater recurrence-free survival with en bloc resection at 60 months (70.7 vs. 28.6 %), this was not statistically significant (p = 0.15) (Fig. 2) .
There was no correlation between recurrence and resection margins. Recurrences were observed in six patients with negative margins (66.7 %; 6/9) with a mean 38.3 ± 37.9 (7-110)
EGD esophagogastroduodenoscopy, ERCP endoscopic retrograde cholangiopancreatography (Fig. 3) . Among the 14 recurrences, a second ampullectomy was performed in four patients (15.4 %; 4/26) at a mean interval of 58.8 ± 39.7 months after the initial ampullectomy. In the remaining ten recurrences, APC fulguration was performed in two patients, and polypectomy with biopsy forceps was performed in the remaining eight patients.
Three patients ultimately had a Whipple procedure performed, but none was performed for ampullary adenoma recurrence. In two cases, the indications were progressive duodenal polyposis with HGD. The Spigelman stages at the time of surgery were III and IV. The third patient elected to have a Whipple procedure because of concerns over future complications with endoscopic surveillance in the setting of prior severe pancreatitis. In this case, the Spigelman stage was II at the time of surgery.
Discussion
As prophylactic colectomy has become the standard of care in FAP patients, concerns over the development of associated extracolonic malignancies have become more prevalent [9] . The management of ampullary adenomas in FAP is not standardized, and we sought to define long-term outcome with an endoscopic approach. We identified a high recurrence rate (58.3 %) of ampullary adenomas following endoscopic ampullectomy over an 85-month period. Adenoma size C10 mm was associated with a higher recurrence rate (76.1 vs. 36.4 %), but there was no correlation with resection method, positive margins, or Spigelman stage of duodenal polyposis. Pancreatitis was the most common complication (19.2 %) of endoscopic ampullectomy, and there were no deaths. No ampullary cancers were identified during follow-up.
Our observed recurrence rate is significantly higher than prior reports [10] [11] [12] . Patel et al. [13] reported a recurrence rate of 16 % after endoscopic ampullectomy over a mean follow-up period of only 17.2 months. Only 9 of the 38 cases in this series were associated with FAP. In another series of 193 patients who underwent endoscopic ampullectomy, most had sporadic disease. The adenoma recurrence rate in the sporadic group was 6 % over a follow-up period of 32 months, but rose to 17 % in the subgroup of 17 FAP patients over a follow-up period of 48 months [14] . Catalano et al. [15] reported on 103 patients undergoing endoscopic ampullectomy, 31 of whom had FAP. A 4 % recurrence rate was observed in the sporadic group versus 23 % in the FAP group over a 36-month follow-up period. Our study was not designed to determine whether recurrent lesions represented re-growth of previously resected adenomas or emergence of new adenomas, and this distinction was difficult to make. However, because our study population was composed entirely of FAP patients, it is reasonable to speculate that the higher rate we observed was Microscopic adenomatous change is relatively common in FAP patients. Burke et al. [16] noted that 54 % of FAP patients harbored ampullary adenomas, even when the ampullae had a normal appearance on direct examination.
In our series, 26.9 % of adenomas were diagnosed histologically when biopsies were obtained of macroscopically normal-appearing ampullae at the original examination, and in 14.3 % of cases at follow-up.
Conclusions
Although the current study is one of the largest series of FAP-associated ampullary adenomas with long-term follow-up, the relatively small number of patients does not permit broad generalizations. However, we suggest endoscopic ampullectomy can be used as a first-line therapeutic option. Recurrences after ampullectomy are much more common than previously appreciated but can be managed safely with additional endoscopic therapy. Follow-up examinations should be accompanied by a biopsy at the ampullectomy site, even if it appears normal endoscopically. Because 9/13 recurrences were diagnosed within 2 years after the initial ampullectomy, we agree with endoscopic surveillance at 6-month intervals in the first 2 years after ampullectomy [17] . Subsequently, annual surveillance is desirable to detect late recurrences. No invasive ampullary cancers were identified during surveillance in our series, suggesting a possible protective benefit of endoscopic ampullectomy. Despite the high recurrence rate, only a minority of patients ultimately required Whipple surgery, and the primary indication for surgery was progressive duodenal polyposis. For those with ampullary adenomas in the setting of advanced duodenal The recurrence-free rate of patients with en bloc resection was much higher than those with piecemeal resection (57.1 vs. 22.2 %); however, it was not statistically significant (p = 0.150) Fig. 3 Risk of adenoma recurrence based upon histologic margins. There was a trend toward a lower recurrence rate in cases with an initial complete resection based upon negative histologic margins. The recurrence-free rate was 33.3 % in patients who had negative margins on their initial ampullectomy specimens, and 46.2 % in patients with positive margins (p = 0.718) polyposis (Spigelman stage IV), surgery may be a more appropriate first-line approach. Because of the correlation between smaller adenoma size and lower risk of recurrence, early recognition and treatment of ampullary adenomas may be warranted in FAP patients.
